RecruitingNot Applicable

Infusion Set Replacement Intervals for Critically Ill Patients

China1,240 participantsStarted 2022-05-15

Plain-language summary

This study aimed to evaluate the efficacy of 24-hour versus 96-hour infusion set replacement to prevent central line-associated bloodstream infection (CLABSI) in critically ill adults with central venous access devices.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 years or older
✓. Able to provide informed consent
✓. Expected length of stay (LOS) \> 96 hours in intensive care unit (ICU)
✓. Need for treatment with central venous access device
✓. The central venous access device is expected to remain in place for at least 96 hours, with infusion set attached

Exclusion criteria

✕. Those who with a bloodstream infection within the previous 48 hours after ICU admission
✕. Those who have their vascular access device actually removed within 96 hours after ICU admission
✕. Those who have participated in other clinical studies within the 2 months

What they're measuring

Central-line associated bloodstream infections (CLABSI) rates

Timeframe: Day 28

Trial details

NCT IDNCT05359601

SponsorZhongnan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-30

Contact for this trial

Bo Hu, MD

+86-18062603223 hobbier1979@163.com

View on ClinicalTrials.gov More Critical Illness trials